Henry Chambers, MD

Professor

Dr. Chambers clinical and research interests are antimicrobial drug resistance, staphylococcal infections, experimental therapeutics, and epidemiology and pathogenesis of disease caused by Staphylococcus aureus. He is editor for the Sanford Guide to Antimicrobial Therapy and he has over 200 original publications and textbook chapters in the areas of drug resistance, endocarditis, bacterial infections, and staphylococcal diseases.

Dr. Chambers received his BA from Centre College in Kentucky and is a graduate of the Vanderbilt University School of Medicine. He trained in Internal Medicine and Infectious Diseases at the University of California San Francisco. Dr. Chambers has been a member of the medical faculty of the UCSF since 1983 where he currently is Professor of Medicine, Medical Director of Clinical Research Services for CTSI. He is an editor for Antimicrobial Agents and Chemotherapy, a reviewer for numerous medical publications, a peer reviewer for NIH study sections.
Education
B.A., - , Centre College Kentucky
Residency, - School of Medicine, University of California, San Francisco
M.D., - School of Medicine, Vanderbilt University
Publications
  1. Ability of Bicarbonate Supplementation to Sensitize Selected Methicillin-Resistant Staphylococcus aureus (MRSA) Strains to ß-Lactam Antibiotics in an Ex Vivo Simulated Endocardial Vegetation Model.
  2. Scope and Predictive Genetic/Phenotypic Signatures of 'Bicarbonate [NaHCO3]-Responsiveness' and ß-Lactam Sensitization Among Methicillin-Resistant Staphylococcus aureus (MRSA).
  3. Is Daptomycin plus Ceftaroline Associated with Better Clinical Outcomes than Standard of Care Monotherapy for Staphylococcus aureus Bacteremia?
  4. Bicarbonate Resensitization of Methicillin-Resistant Staphylococcus aureus to ß-Lactam Antibiotics.
  5. A prognostic model of persistent bacteremia and mortality in complicated S. aureus bloodstream infection.
  6. Omadacycline - The Newest Tetracycline.
  7. Structural and kinetic analysis of penicillin-binding protein 4 (PBP4)-mediated antibiotic resistance in Staphylococcus aureus.
  8. Essential Resources and Strategies for Antibiotic Stewardship Programs in the Acute Care Setting.
  9. PBP4: A New Perspective on Staphylococcus aureus ß-Lactam Resistance.
  10. PBP4 activity and its overexpression are necessary for PBP4-mediated high-level ß-lactam resistance.
  11. PBP4 Mediates ß-Lactam Resistance by Altered Function.
  12. Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus.
  13. Antimicrobial Stewardship Approaches in the Intensive Care Unit.
  14. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses.
  15. High-Level Resistance of Staphylococcus aureus to ß-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4).
  16. Can Ceftazidime-Avibactam and Aztreonam Overcome ß-Lactam Resistance Conferred by Metallo-ß-Lactamases in Enterobacteriaceae?
  17. The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress.
  18. Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.
  19. Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.
  20. IVIG-mediated protection against necrotizing pneumonia caused by MRSA.
  21. Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.
  22. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.
  23. Daptomycin-ß-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis.
  24. PBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in Staphylococcus aureus.
  25. Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance.
  26. Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis.
  27. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections.
  28. Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.
  29. Probability of eradication using vancomycin alone or in combination for methicillin-resistant Staphylococcus aureus bacteremia.
  30. Pharmacology and the treatment of complicated skin and skin-structure infections.
  31. Global gene expression of methicillin-resistant Staphylococcus aureus USA300 during human and mouse infection.
  32. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia.
  33. Epidemiologic Similarities in Pediatric Community-Associated Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus in the San Francisco Bay Area.
  34. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus.
  35. Does doxycycline protect against development of Clostridium difficile infection?
  36. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300.
  37. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.
  38. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
  39. A mecA-negative strain of methicillin-resistant Staphylococcus aureus with high-level ß-lactam resistance contains mutations in three genes.
  40. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury.
  41. Community-associated meticillin-resistant Staphylococcus aureus.
  42. Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid.
  43. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.
  44. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era.
  45. Waves of resistance: Staphylococcus aureus in the antibiotic era.
  46. Coming home with MRSA.
  47. Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300.
  48. Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response.
  49. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus.
  50. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
  51. Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
  52. Recurrence of skin and soft tissue infection caused by methicillin-resistant Staphylococcus aureus in a HIV primary care clinic.
  53. Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis.
  54. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005.
  55. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus.
  56. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus.
  57. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus.
  58. Determining whether methicillin-resistant Staphylococcus aureus is associated with health care.
  59. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men.
  60. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection.
  61. Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin?
  62. Intermediate vancomycin susceptibility in a community-associated MRSA clone.
  63. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
  64. Ophthalmic manifestations of infections caused by the USA300 clone of community-associated methicillin-resistant Staphylococcus aureus.
  65. Diabetic ketoacidosis precipitated by Staphylococcus aureus abscess and bacteremia due to acupuncture: case report and review of the literature.
  66. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin.
  67. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
  68. Imipenem for treatment of tuberculosis in mice and humans.
  69. Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area.
  70. Role of SraP, a Serine-Rich Surface Protein of Staphylococcus aureus, in binding to human platelets.
  71. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
  72. Impact of a formulary switch from ticarcillin-clavulanate to piperacillin-tazobactam on colonization with vancomycin-resistant enterococci.
  73. An epidemic of methicillin-resistant Staphylococcus aureus soft tissue infections among medically underserved patients.
  74. Crystal structures of the Apo and penicillin-acylated forms of the BlaR1 beta-lactam sensor of Staphylococcus aureus.
  75. Origins of community strains of methicillin-resistant Staphylococcus aureus.
  76. API 20 strep identification system may incorrectly speciate enterococci with low level resistance to vancomycin.
  77. PBP 2a mutations producing very-high-level resistance to beta-lactams.
  78. Community-acquired Methicillin-resistant Staphylococcus aureus: Epidemiology and Potential Virulence Factors.
  79. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.
  80. Jumping the barrier to beta-lactam resistance in Staphylococcus aureus.
  81. Solving staphylococcal resistance to beta-lactams.
  82. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis.
  83. Methicillin-resistant staphylococci and their treatment in the intensive care unit.
  84. Effect of disruption of Staphylococcus aureus PBP4 gene on resistance to beta-lactam antibiotics.
  85. Epidemiology of vancomycin-resistant Enterococcus faecium under a selective isolation policy at an urban county hospital.
  86. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco.
  87. Identifying pulmonary tuberculosis in patients with negative sputum smear results.
  88. A proteolytic transmembrane signaling pathway and resistance to beta-lactams in staphylococci.
  89. The changing epidemiology of Staphylococcus aureus?
  90. Methicillin-resistant Staphylococcus aureus. Mechanisms of resistance and implications for treatment.
  91. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.
  92. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
  93. Suppurative parotitis.
  94. Activity of amoxicillin/clavulanate in patients with tuberculosis.
  95. Cloning and sequence analysis of a class A beta-lactamase from Mycobacterium tuberculosis H37Ra.
  96. Burden of Mycobacterium tuberculosis in sputum samples can be reliably determined using a quantitative, non-radioactive polymerase chain reaction assay.
  97. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
  98. Treatment of Staphylococcus aureus catheter-related infection and infective endocarditis with granulocyte colony-stimulating factor in the experimental rabbit model.
  99. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine.
  100. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?
  101. Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay.
  102. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits.
  103. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a.
  104. Point mutations in Staphylococcus aureus PBP 2 gene affect penicillin-binding kinetics and are associated with resistance.
  105. Altered production of penicillin-binding protein 2a can affect phenotypic expression of methicillin resistance in Staphylococcus aureus.
  106. Efficacy of cefoperazone in combination with sulbactam in experimental Staphylococcus aureus endocarditis in rabbits.
  107. Detection of methicillin-resistant staphylococci.
  108. blaI and blaR1 regulate beta-lactamase and PBP 2a production in methicillin-resistant Staphylococcus aureus.
  109. Short-course combination and oral therapies of Staphylococcus aureus endocarditis.
  110. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus.
  111. Characterization of penicillin-binding protein 2 of Staphylococcus aureus: deacylation reaction and identification of two penicillin-binding peptides.
  112. Comparison of conventional susceptibility tests with direct detection of penicillin-binding protein 2a in borderline oxacillin-resistant strains of Staphylococcus aureus.
  113. Effect of protein binding of daptomycin on MIC and antibacterial activity.
  114. Borderline susceptibility to antistaphylococcal penicillins is not conferred exclusively by the hyperproduction of beta-lactamase.
  115. Treatment of infection and colonization caused by methicillin-resistant Staphylococcus aureus.
  116. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus.
  117. Characterization of mechanisms of resistance to beta-lactam antibiotics in methicillin-resistant strains of Staphylococcus saprophyticus.
  118. Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus.
  119. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.
  120. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.
  121. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin.
  122. Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits.
  123. Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits.
  124. Methicillin-resistant staphylococci: detection methods and treatment of infections.
  125. Methicillin-resistant staphylococci: genetics and mechanisms of resistance.
  126. Low-level methicillin resistance in strains of Staphylococcus aureus.
  127. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy.
  128. Methicillin-resistant staphylococci.
  129. Coagulase-negative staphylococci resistant to beta-lactam antibiotics in vivo produce penicillin-binding protein 2a.
  130. Effect of NaCl and nafcillin on penicillin-binding protein 2a and heterogeneous expression of methicillin resistance in Staphylococcus aureus.
  131. Comparative activity of CGP 31608, nafcillin, cefamandole, imipenem, and vancomycin against methicillin-susceptible and methicillin-resistant staphylococci.
  132. Emergence of resistance to cephalothin and gentamicin during combination therapy for methicillin-resistant Staphylococcus aureus endocarditis in rabbits.
  133. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus.
  134. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus.
  135. Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin.
  136. Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus.
  137. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus.
  138. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.
  139. Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro.
  140. Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts.